Annual report pursuant to Section 13 and 15(d)

Restatement of Financial Statements

v3.21.1
Restatement of Financial Statements
6 Months Ended
Dec. 31, 2020
Restatement [Abstract]  
Restatement of Financial Statements
Note 2
Restatement of Financial Statements
In April 2021, the Company concluded that, because of a misapplication of the accounting guidance related to its Public and Private Placement warrants the Company issued in September 2020, the Company’s previously issued financial statements for the Affected Periods should no longer be relied upon. As such, the Company is restating its financial statements for the Affected Periods included in this Annual Report.
On April 12, 2021, the staff of the Securities and Exchange Commission (the “SEC Staff”) issued a public statement entitled “Staff Statement on Accounting and Reporting Considerations for Warrants issued by Special Purpose Acquisition Companies (“SPACs”) (the “SEC Staff Statement”). In the SEC Staff Statement, the SEC Staff expressed its view that certain terms and conditions common to SPAC warrants may require the warrants to be classified as liabilities on the SPAC’s balance sheet as opposed to equity. Since issuance on September 21, 2020 the Company’s warrants were accounted for as equity within the Company’s previously reported balance sheets, and after discussion and evaluation, including with the Company’s independent auditors, management concluded that the warrants should be presented as liabilities with subsequent fair value remeasurement.
Historically, the Warrants were reflected as a component of equity as opposed to liabilities on the balance sheets and the statements of operations did not include the subsequent non-cash changes in estimated fair value of the Warrants, based on our application of FASB ASC Topic 815-40,
 
Derivatives and Hedging, Contracts in Entity’s Own Equity
 
(“ASC 815-40”). The views expressed in the SEC Staff Statement were not consistent with the Company’s historical interpretation of the specific provisions within its warrant agreement and the Company’s application of ASC 815-40 to the warrant agreement. The Company reassessed its accounting for Warrants issued on September 21, 2020, in light of the SEC Staff’s published views. Based on this reassessment, management determined that the Warrants should be classified as liabilities measured at fair value upon issuance, with subsequent changes in fair value reported in the Company Statement of Operations each reporting period.
Therefore, the Company, in consultation with its Audit Committee, concluded that its previously issued financial statements for the periods beginning with the period from July 3, 2020 through December 31, 2020 and the period from July 3, 2020 through September 30, 2020 (collectively, the “Affected Periods”) should be restated because of a misapplication in the guidance around accounting for certain of our outstanding warrants to purchase ordinary shares (the “Warrants”) and should no longer be relied upon. The Warrants were issued in connection with the Company’s Initial Public Offering of 69,000,000 Units and the sale of Private Placement warrants completed on September 21, 2020. Each Unit consists of one of the Company’s Class A ordinary shares, $0.0001 par value, and one-quarter of one redeemable warrant. Each whole Warrant entitles the holder to purchase one of Class A ordinary share at a price of $11.50 per share. The Warrants will expire worthless five years from the date of completion of our initial business combination. The material terms of the warrants are more fully described in Note 8—Derivative Warrant Liabilities. See revised Note 9 – Fair Value Measurements.

 
Impact of the Restatement
The impact of the restatement on the balance sheets, statements of operations and statements of cash flows for the Affected Periods is presented below. The restatement had no impact on net cash flows from operating, investing or financing activities.
The tables below present the effect of the financial statement adjustments related to the restatement discussed above of the Company’s previously reported financial statements as of and for the period from July 3, 2020 (inception) through December 31, 2020:
 
    
As of December 31, 2020
 
    
As Previously
Reported
   
Restatement
Adjustment
   
As Restated
 
Balance Sheet
      
Total assets
   $ 692,373,510     $ —       $ 692,373,510  
  
 
 
   
 
 
   
 
 
 
Liabilities and shareholders’ equity
      
Total current liabilities
   $ 421,572     $ —       $ 421,572  
Deferred legal fees
     239,161       —         239,161  
Deferred underwriting commissions
     24,150,000         24,150,000  
Derivative warrant liabilities
     —         99,938,040       99,938,040  
  
 
 
   
 
 
   
 
 
 
Total liabilities
     24,810,733       99,938,040       124,748,773  
Class A common stock, $0.0001 par value; shares subject to possible redemption
     662,562,770       (99,938,040     562,624,730  
Shareholders’ equity
      
Preferred stock- $0.0001 par value
     —         —         —    
Class A common stock - $0.0001 par value
     274       1,000       1,274  
Class B common stock - $0.0001 par value
     1,725       —         1,725  
Additional
 
paid-in-capital
     5,931,243       62,968,350       68,899,593  
Accumulated deficit
     (933,235     (62,969,350     (63,902,585
  
 
 
   
 
 
   
 
 
 
Total shareholders’ equity
     5,000,007       —         5,000,007  
  
 
 
   
 
 
   
 
 
 
Total liabilities and shareholders’ equity
   $ 692,373,510     $ —       $ 692,373,510  
  
 
 
   
 
 
   
 
 
 
 
    
Period From July 3, 2020 (Inception) Through
December 31, 2020
 
    
As Previously
Reported
   
Restatement
Adjustment
   
As Restated
 
Statement of Operations
      
Loss from operations
   $ (1,104,601   $ —       $ (1,104,601
Other (expense) income:
      
Change in fair value of warrant liabilities
     —         (61,680,150     (61,680,150
Financing costs
     —         (1,289,200     (1,289,200
Unrealized gain on investments held in Trust Account
     171,366       —         171,366  
  
 
 
   
 
 
   
 
 
 
Total other (expense) income
     171,366       (62,969,350     (62,797,984
  
 
 
   
 
 
   
 
 
 
Net loss
   $ (933,235   $ (62,969,350   $ (63,902,585
  
 
 
   
 
 
   
 
 
 
Basic and Diluted weighted-average Class A common stock outstanding
     69,000,000             69,000,000  
  
 
 
   
 
 
   
 
 
 
Basic and Diluted net loss per Class A common shares
   $ 0.00           $ —    
  
 
 
   
 
 
   
 
 
 
Basic and Diluted weighted-average Class B common stock outstanding
     17,250,000             17,250,000  
  
 
 
   
 
 
   
 
 
 
Basic and Diluted net loss per Class B common shares
   $ (0.05   $ (3.65   $ (3.70
  
 
 
   
 
 
   
 
 
 
 
    
Period From July 3,2020 (Inception) Through
December 31, 2020
 
    
As Previously
Reported
    
Restatement
Adjustment
   
As Restated
 
Statement of Cash Flows
       
Net loss
   $ (933,235)      $ (62,969,350   $ (63,902,585
Adjustments to reconcile net loss to net cash used in operating activities
     (146,366)        62,969,350       62,822,984  
Net cash used in operating activities
     (1,165,494)        —         (1,165,494
Net cash used in investing activities
     (690,000,000)        —         (690,000,000
Net cash provided by financing activities
     692,860,173        —         692,860,173  
  
 
 
    
 
 
   
 
 
 
Net change in cash
  
$
1,694,679
 
  
$
—  
 
 
$
1,694,679
 
  
 
 
    
 
 
   
 
 
 

In addition, the impact to the balance sheet dated September 18, 2020, filed on Form 8-K on September 25, 2020 related to the impact of accounting for the public and private warrants as liabilities at fair value resulted in a $38.3 million increase to the derivative warrant liabilities line item at September 18, 2020 and offsetting decrease to the Class A common stock subject to possible redemption mezzanine equity line item. The table below presents the effect of the financial statement adjustments related to the restatement discussed above of the Company’s previously reported balance sheet dated September 18, 2020.
 
    
As of September 21, 2020
 
    
As Previously
Reported
   
Restatement
Adjustment
   
As Restated
 
Unaudited Condensed Balance Sheet
      
Total assets
   $ 694,363,065     $ —       $ 694,363,065  
  
 
 
   
 
 
   
 
 
 
Liabilities and shareholders’ equity
      
Total current liabilities
   $ 1,790,393     $ —       $ 1,790,393  
Deferred underwriting commissions
     24,150,000       —         24,150,000  
Derivative warrant liabilities
     —         38,257,890       38,257,890  
  
 
 
   
 
 
   
 
 
 
Total liabilities
     25,940,393       38,257,890       64,198,283  
Class A common stock, $0.0001 par value; shares subject to possible redemption shareholders’ equity
     663,422,670       (38,257,890     625,164,780  
Preferred stock- $0.0001 par value
     —         —         —    
Class A common stock - $0.0001 par value
     266       382       648  
Class B common stock - $0.0001 par value
     1,725       —         1,725  
Additional paid-in-capital
     5,071,351       1,288,818       6,360,169  
Accumulated deficit
     (73,340     (1,289,200     (1,362,540
  
 
 
   
 
 
   
 
 
 
Total shareholders’ equity
     5,000,002       —         5,000,002  
  
 
 
   
 
 
   
 
 
 
Total liabilities and shareholders’ equity
   $ 694,363,065     $ —       $ 694,363,065